NCT05454241CompletedPhase 2
CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies
Efficacy, Safety and PK of CD7 CAR-T in Patients With Relapsed or Refractory CD7+ Hematological Malignancies
Source: ClinicalTrials.gov · Last updated 13 Mar 2025
Brief summary (registry, in English)
This is a open-label, phase 2 study to evaluate the efficacy, safety and PK of CD7 chimeric antigen receptors treatment for patients with refractory/relapsed CD7 positive hematological malignancies.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 14 (actual)
- First submitted
- 4 Jul 2022
- Start date
- 7 Sept 2022
- Primary completion date
- 31 Aug 2024
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Diseases
- Childhood cancers
- NCT number
- NCT05454241
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 14
- From 7 Sept 2022 to the primary completion date, 31 Aug 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with history of epilepsy or other central nervous system diseases;
- Patients with uncontrolled active infection.
- Positive for any of the following etiological tests: HIV, HBV, HCV
- Any other conditions that researcher think it is inappropriate for the subject to anticipate the trial
Lab values
- Patients with prolonged QT or severe heart disease;
Other
- Pregnant or lactating women
Who the study is looking for
- Diagnosed CD7 positive relapsed/refractory hematological malignancies.
- Echocardiography shows left ventricular ejection fraction (LVEF) ≥ 50%;
- There is no active pulmonary infection, and the oxygen saturation during air inhalation is more than 92%;
- The estimated survival time is more than 3 months;
- Eastern cooperative oncology group (ECOG) performance status of 0 to 2
- The patients or their legal guardians voluntarily participated in the trial and signed the informed consent.
Age in the registry: 3 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institute of Hematology & Blood Diseases Hospital Coordinator of this site? Confirm its status | Tianjin | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.